Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
OMCL logo OMCL
Upturn stock ratingUpturn stock rating
OMCL logo

Omnicell Inc (OMCL)

Upturn stock ratingUpturn stock rating
$33.28
Last Close (24-hour delay)
Profit since last BUY7.04%
upturn advisory
Consider higher Upturn Star rating
BUY since 17 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: OMCL (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $44

1 Year Target Price $44

Analysts Price Target For last 52 week
$44 Target price
52w Low $22.66
Current$33.28
52w High $55.74

Analysis of Past Performance

Type Stock
Historic Profit 27.53%
Avg. Invested days 39
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.53B USD
Price to earnings Ratio 66.56
1Y Target Price 44
Price to earnings Ratio 66.56
1Y Target Price 44
Volume (30-day avg) 8
Beta 0.78
52 Weeks Range 22.66 - 55.74
Updated Date 08/29/2025
52 Weeks Range 22.66 - 55.74
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.5

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-07-30
When Before Market
Estimate 0.2622
Actual 0.45

Profitability

Profit Margin 2.01%
Operating Margin (TTM) 2.8%

Management Effectiveness

Return on Assets (TTM) 0.49%
Return on Equity (TTM) 1.87%

Valuation

Trailing PE 66.56
Forward PE 29.5
Enterprise Value 1501468873
Price to Sales(TTM) 1.33
Enterprise Value 1501468873
Price to Sales(TTM) 1.33
Enterprise Value to Revenue 1.31
Enterprise Value to EBITDA 14.62
Shares Outstanding 45934300
Shares Floating 44819427
Shares Outstanding 45934300
Shares Floating 44819427
Percent Insiders 1.79
Percent Institutions 105.73

ai summary icon Upturn AI SWOT

Omnicell Inc

stock logo

Company Overview

overview logo History and Background

Omnicell Inc. was founded in 1992. Initially focused on medication dispensing automation, it has grown through innovation and acquisitions to become a leading provider of medication management and adherence solutions for healthcare systems and pharmacies.

business area logo Core Business Areas

  • Medication Management Solutions: Provides automated dispensing systems, inventory management software, and analytics to improve medication management in hospitals and other healthcare facilities.
  • Medication Adherence Solutions: Offers solutions for retail and specialty pharmacies, including adherence packaging, automation, and patient engagement tools, aimed at improving patient adherence to medication regimens.

leadership logo Leadership and Structure

The leadership team includes Randall Lipps (Chairman, President, and CEO). The company has a typical corporate structure with departments focused on sales, marketing, R&D, operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • XT Automated Dispensing Cabinets: Automated medication dispensing system used in hospitals. Competitors include BD (Becton, Dickinson and Company), Capsa Healthcare and Swisslog Healthcare. Market share for Omnicell ADC estimated at approximately 20-25%.
  • Central Pharmacy Automation: Solutions for central pharmacies to automate medication compounding, packaging, and dispensing. Competitors include iRxFill, ARxIUM, and RxSafe.
  • EnlivenHealth: Patient engagement and adherence platform for retail pharmacies. Competitors include Amplicare, PrescribeWellness, and Outcome Health.

Market Dynamics

industry overview logo Industry Overview

The healthcare automation market is growing due to increasing labor costs, medication errors, and the need for improved efficiency in healthcare facilities. The market is driven by technological advancements, regulatory requirements, and the growing geriatric population.

Positioning

Omnicell is a leading provider of medication management and adherence solutions, positioned to capitalize on the growing demand for automation in healthcare. It competes on innovation, product breadth, and customer service.

Total Addressable Market (TAM)

Estimated at $10-15 billion globally. Omnicell is positioned to address a significant portion of this TAM through its comprehensive product portfolio.

Upturn SWOT Analysis

Strengths

  • Broad product portfolio
  • Strong customer relationships
  • Established market presence
  • Innovative technology
  • Acquisition Strategy

Weaknesses

  • Integration challenges from acquisitions
  • High debt levels
  • Dependence on hospital capital spending
  • Product recalls
  • Cybersecurity Risk

Opportunities

  • Expanding into new geographic markets
  • Developing new medication adherence solutions
  • Increasing adoption of automation in pharmacies
  • Growing demand for remote pharmacy services
  • Partnerships with healthcare providers and payers

Threats

  • Increased competition
  • Regulatory changes
  • Economic downturn
  • Technological obsolescence
  • Cybersecurity threats

Competitors and Market Share

competitor logo Key Competitors

  • BDX
  • Baxter
  • ARX

Competitive Landscape

Omnicell competes with larger companies that have broader product portfolios. Its strengths lie in specialized expertise in medication management and a focus on innovation.

Major Acquisitions

ReCept Pharmacy

  • Year: 2021
  • Acquisition Price (USD millions): 290
  • Strategic Rationale: Expanded Omnicell's presence in the 340B market.

Performance Analytics (PAAS)

  • Year: 2021
  • Acquisition Price (USD millions): 185
  • Strategic Rationale: Acquisition provided advanced analytics and business intelligence solutions for pharmacy operations.

Growth Trajectory and Initiatives

Historical Growth: Omnicell's historical growth has been driven by a combination of organic expansion and strategic acquisitions.

Future Projections: Analysts project continued revenue growth driven by increasing demand for automation in healthcare and expansion into new markets.

Recent Initiatives: Recent initiatives include the launch of new medication adherence solutions, expansion of cloud-based services, and strategic acquisitions to expand product offerings and market reach.

Summary

Omnicell is a prominent player in the medication management and adherence solutions market, benefiting from increasing demand for healthcare automation. However, high debt and acquisition integration could be issues. To capitalize on growth, Omnicell must manage its debt, streamline operations, and maintain a strong focus on innovation. Increased competition and economic pressures are important external risks to consider.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (10-K, 10-Q)
  • Analyst reports
  • Industry publications
  • Company Website

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Omnicell Inc

Exchange NASDAQ
Headquaters Fort Worth, TX, United States
IPO Launch date 2001-08-07
Founder, Executive Chairman, President & CEO Mr. Randall A. Lipps
Sector Healthcare
Industry Health Information Services
Full time employees 3650
Full time employees 3650

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.